41 Recruiting Multiple Myeloma Phase 3 Clinical Trials
Active phase 3 studies for multiple myeloma enrolling across the USA. Verify eligibility and contact site coordinators.
All Multiple Myeloma studiesPhase 3 Studies for Multiple Myeloma
🔵 Active, Not Recruiting Phase3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
📍 Local Institution - 0131 — Los Angeles, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
📍 Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
📍 UCLA Medical Center — Los Angeles, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
📍 Rocky Mountain Cancer Centers — Aurora, Colorado
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
📍 UCSF — San Francisco, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
📍 UCSF Fresno — Clovis, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
📍 Banner Gateway Medical Center — Gilbert, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Daratumumab
📍 University of Miami Sylvester Cancer Center — Miami, Florida
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
📍 The University of Arizona Cancer Center — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
📍 Providence Hospital — Mobile, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
📍 University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy — Little Rock, Arkansas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
📍 University of Arkansas — Little Rock, Arkansas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Yuma, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
📍 University of Arkansas for Medical Sciences/Myeloma Institute — Little Rock, Arkansas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 035 — Hot Springs, Arkansas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham - Main /ID# 261434 — Birmingham, Alabama
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase3
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
📍 Infirmary Health - Diagnostic & Medical Clinic (DMC) — Mobile, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
📍 Gundersen Lutheran — La Crosse, Wisconsin
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alabama Oncology — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Phoenix — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
📍 Jupiter Medical Center/Anderson Family Cancer Institute — Jupiter, Florida
View Study & Checklist ➔ 🟢 Recruiting Phase3
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
📍 Wellstar MCG — Augusta, Georgia
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
📍 Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase2 / Phase3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
📍 Mayo Clinic Hospital Scottsdale /ID# 278349 — Scottsdale, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase3
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
📍 Cross Cancer Institute — Edmonton, Alberta
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
📍 Clovis Community Medical Center — Clovis, California
View Study & Checklist ➔ 🟢 Recruiting Phase3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
📍 Infirmary Cancer Care — Mobile, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
📍 GSK Investigational Site — Mobile, Alabama
View Study & Checklist ➔